Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

How to confront antisemitism, deal with protests — and respect free speech

Is student loan debt an emergency? Take our quiz.

Humans might need to re-engineer the climate

The Rick Steves guide to life

The sad, stale state of in-flight vegetarian meals

How to train for a marathon on vacation

Brave Little Hunter is free: Baby orca escapes lagoon for open seas

Soldiers reunite with their pets from overseas: ‘It meant everything to me’

Chiropractor works on giraffe, is nuzzled: ‘Giraffes are just giant dogs?’

An AI blood test purports to diagnose postpartum depression

Meta’s oversight body prepares to lay off workers

A TikTok ban could also end short-form video as we’ve come to know it

In a ‘meat grinder’ of a war, Russian and Ukrainian casualties rise

Middle East conflict live updates: Netanyahu vows to invade Rafah regardless of cease-fire deal; Blinken in region

Parenting in Gaza today is so much more than keeping your children alive

Trump and allies say Biden pays rent for ‘illegals’ in Michigan. Not true.

Eighty percent of Ukraine-Israel bill will be spent in U.S. or by U.S. military

Facts in the Trump courtroom v. ‘facts’ in the court of public opinion

A new measure of ‘Trump amnesia’ in swing states

Harsh deportation tools are just fine with many Americans

How the Biden impeachment push echoes Trump’s effort to retain power

Ask Amy: Why did my friend lie about seeing my ex-girlfriend?

Carolyn Hax: Her family left all the kitchen work to her, so she went on strike

Miss Manners: Some audience members ask rambling questions post-lecture

Americans are sleeping more than ever. See how you compare.

Where seas are rising at alarming speed 

The new face of flooding

Nationals sweep away the Marlins to get back to .500

The Rangers swept the Capitals, and it’s time for the new core to take charge

Jayden Daniels is latest in Washington’s checkered history of first-round QBs

Trump trial live updates: Witness testimony continues with Keith Davidson

Trump Hush Money

Suzanne McCarroll, a television news reporter in Denver, had been in remission from non-Hodgkin lymphoma for almost eight years when the cancer returned in May 2015. She had a stem-cell transplant, but the disease came back again in January. What, she wondered, should she do now?

After talking to her doctor and her brother, a neurobiologist at Harvard, McCarroll enrolled in an early-stage clinical trial using immunotherapy at Fred Hutchinson Cancer Researcher Center in Seattle.

“It’s like taking your car to a mechanic,” McCarroll said. “At some point, you have to trust someone who knows more than you do.”

The trial was testing CAR T-cell therapy — in which immune cells are removed from the patient, genetically engineered to attack cancer cells and then reinfused — in patients with leukemia and non-Hodgkin lymphoma. On Thursday, test results showed that McCarroll was in remission and could head home to Colorado. McCarroll, who is 60, was one of the first patients treated at a new outpatient clinic at the cancer center, which is scheduled to open officially in December.

Gary Gilliland, president and director of the cancer center, said in an interview that the clinic is unique in many ways. He said that it is the only stand-alone immunotherapy clinic that focuses primarily on using engineered T cells — and employs a strategy pioneered by Hutchinson to increase the T cells' cancer-fighting ability.

After removing T cells from the patients, he said, scientists remove nonessential immune cells, resulting in a specific ratio of engineered helper and killer T cells. Hutchinson scientists say they believe the approach increases the growth of the cells when they are returned to patients, and may be the reason for the center’s impressive results in clinical trials involving patients with blood cancers.

In creating the clinic, Gilliland said, the cancer center is sending a broader message: “We believe these therapies have curative potential.”

Immunotherapy has emerged as the hottest field in medicine, with much of the focus on two new types of treatments: CAR T-cell therapy, which is still experimental and has mostly been used for blood cancers, and “checkpoint inhibitors,” which has been approved for solid tumors, such as melanoma and lung cancer. Researchers are encouraged by the results, but caution that much more needs to be understood to make immunotherapy work for all patients and to stave off relapse, which is still a major issue. Combinations of the approaches are now being tested at Hutchinson and across the country.

The new Hutchinson facility will be named the Bezos Family Immunotherapy Clinic, reflecting $30 million in previous donations made by Jackie and Mike Bezos for the cancer center's immunotherapy work, Gilliland said. (Their son, Jeffrey P. Bezos, owns The Washington Post.) The contributions weren't used for the clinic, which cost $7.2 million. Philanthropists have emerged as a major force in funding immunotherapy, with Sean Parker, Michael R. Bloomberg and Stanley Kimmel, among others, making sizable contributions to other medical centers.

David Maloney, who is the clinic’s first medical director, said the new facility will allow physicians to closely monitor patients for potential safety problems and to learn why some patients respond to immunotherapy and others don’t. The new clinic also will allow researchers to ramp up the number of clinical trials. He said the clinic is “patient centered,” with services and physicians coming to the patient, rather than the other way around, and with easy movement between the clinic and the research lab.

<a href="https://www.washingtonpost.com/news/to-your-health/wp/2016/09/28/cancer-immunotherapy-is-moving-fast-heres-what-you-need-to-know-now/">FAQ: What you need to know about immunotherapy</a>

<a href="https://www.washingtonpost.com/news/to-your-health/wp/2016/09/07/cancer-moonshot-panel-names-top-10-ways-to-">Moonshot panel names 10 ways to speed progress against cancer</a>

Part of Wall Street Journal team that won the 1997 Pulitzer Prize for national reporting on AIDS 

Syracuse University, BS in journalism

Laurie McGinley covers health and medicine for The Washington Post. She focuses on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health, science and environment editor. 

Laurie McGinley

The Washington Post

Health Care

Medical Mysteries

Science

Well+Being

Health

prism://prism.query/site,/health&limit=20

The Washington Post health section provides coverage and analysis of health, healthcare, nutrition and fitness news.